GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » Shiller PE Ratio

Adverum Biotechnologies (Adverum Biotechnologies) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adverum Biotechnologies Shiller PE Ratio Historical Data

The historical data trend for Adverum Biotechnologies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Shiller PE Ratio Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adverum Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adverum Biotechnologies's Shiller PE Ratio

For the Biotechnology subindustry, Adverum Biotechnologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Shiller PE Ratio falls into.



Adverum Biotechnologies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Adverum Biotechnologies's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Adverum Biotechnologies's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.3/129.4194*129.4194
=-2.300

Current CPI (Dec. 2023) = 129.4194.

Adverum Biotechnologies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.800 99.695 -1.039
201406 -4.007 100.560 -5.157
201409 -5.000 100.428 -6.443
201412 -4.567 99.070 -5.966
201503 -3.800 99.621 -4.937
201506 -3.800 100.684 -4.885
201509 -5.500 100.392 -7.090
201512 -5.450 99.792 -7.068
201603 -5.700 100.470 -7.342
201606 -17.600 101.688 -22.400
201609 -3.500 101.861 -4.447
201612 -5.400 101.863 -6.861
201703 -3.800 102.862 -4.781
201706 -2.700 103.349 -3.381
201709 -3.200 104.136 -3.977
201712 -3.200 104.011 -3.982
201803 -3.000 105.290 -3.688
201806 -3.000 106.317 -3.652
201809 -3.400 106.507 -4.131
201812 -2.400 105.998 -2.930
201903 -2.300 107.251 -2.775
201906 -2.300 108.070 -2.754
201909 -2.500 108.329 -2.987
201912 -3.000 108.420 -3.581
202003 -3.100 108.902 -3.684
202006 -3.600 108.767 -4.284
202009 -3.100 109.815 -3.653
202012 -3.900 109.897 -4.593
202103 -2.900 111.754 -3.358
202106 -4.500 114.631 -5.081
202109 -3.900 115.734 -4.361
202112 -3.500 117.630 -3.851
202203 -3.800 121.301 -4.054
202206 -4.400 125.017 -4.555
202209 -4.000 125.227 -4.134
202212 -3.300 125.222 -3.411
202303 -2.900 127.348 -2.947
202306 -3.100 128.729 -3.117
202309 -3.300 129.860 -3.289
202312 -2.300 129.419 -2.300

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adverum Biotechnologies  (NAS:ADVM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Adverum Biotechnologies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (Adverum Biotechnologies) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Executives
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Setareh Seyedkazemi officer: Chief Development Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Linda M Rubinstein officer: Chief Financial Officer 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Peter Soparkar officer: Chief Legal Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Brigit Riley officer: Chief Scientific Officer 100 CARDINAL WAY, REDWOOD CITY CA 94063
Laurent Fischer director, officer: CEO and Director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota officer: Principal Accounting Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow officer: SVP, Genl Counsel, Acting CFO C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza officer: Chief Financial Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong director C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden director C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Julie Clark officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063

Adverum Biotechnologies (Adverum Biotechnologies) Headlines

From GuruFocus

Adverum Biotechnologies Announces New Executive Leadership Roles

By sperokesalga sperokesalga 05-25-2023